Comparative Pharmacology
Head-to-head clinical analysis: MACROBID versus UREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROBID versus UREX.
MACROBID vs UREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
Urex (methenamine hippurate) is hydrolyzed in acidic urine to formaldehyde and ammonia. Formaldehyde denatures bacterial proteins and nucleic acids, exerting a nonspecific bactericidal effect. The hippuric acid component maintains urinary acidity.
100 mg orally twice daily with food for 7 days.
100 mg orally twice daily for 3 days (uncomplicated UTI) or 100 mg orally once daily for 5 days (prophylaxis).
None Documented
None Documented
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
Terminal elimination half-life is 14-18 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 40 hours in severe impairment), necessitating dose adjustment.
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination accounts for <5%.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective